The Omission of Anthracycline Chemotherapy in Women with Early HER2-Negative Breast Cancer-A Systematic Review and Meta-Analysis.
Danilo Giffoni de Mello Morais MataMary-Beth RushMegan Smith-UffenJawaid YounusAna Elisa LohmannMaureen E TrudeauRebecca L MorganPublished in: Current oncology (Toronto, Ont.) (2024)
Overall, there was no difference between TC and anthracycline-taxane in DFS, OS and cardiotoxicity. In women with ≥4 nodes, anthracycline-taxane was associated with a substantial reduction in relapse events, compared to TC. Our study supports the current standard of practice, which is to use anthracycline-taxane and TC chemotherapy as a reasonable option in select cases.